Quanterix Corporation (QTRX)
|52 Week Range||10.02-28.77|
|1y Target Est||-|
|DCF Unlevered||QTRX DCF ->|
|DCF Levered||QTRX LDCF ->|
|Debt / Equity||12.00%||Neutral|
Upgrades & Downgrades
Latest QTRX news
Here's Why Quanterix Corporation (QTRX) is a Great Momentum Stock to Buy
4 December 2023
Does Quanterix Corporation (QTRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 54.88% Upside in Quanterix Corporation (QTRX): Can the Stock Really Move ...
13 November 2023
The mean of analysts' price targets for Quanterix Corporation (QTRX) points to a 54.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...
Quanterix Corporation (QTRX) Q3 2023 Earnings Call Transcript
7 November 2023
Quanterix Corporation (NASDAQ:QTRX ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Ed Joyce - VP, IR Masoud Toloue - President and CEO Vandana Sriram - CFO Conferen...
7 Stocks to Buy if You Anticipate a Hot November
6 November 2023
While enough evidence exists that justify a pessimistic view of the market – in particular, high inflation and high borrowing costs – it's also possible that a hot November could rejuvenate previously...
Quanterix Corporation: Going For Three In A Row
6 November 2023
Today, we revisit Quanterix Corporation, a life sciences company that develops and markets digital immunoassay platforms. The company has posted much better than expected quarterly numbers over the pa...
Quanterix Corporation (QTRX) Moves 7.2% Higher: Will This Strength Last?
28 September 2023
Quanterix Corporation (QTRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the ...
Quanterix: Advancing sNfL Reference Ranges In Pediatric Neurology
24 August 2023
Quanterix specializes in ultra-sensitive digital immunoassay platforms for early disease detection, potentially transforming disease management. The company's financials show promising growth, with to...
Quanterix Corporation (QTRX) Reports Q2 Loss, Tops Revenue Estimates
7 August 2023
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.67 per share a year ago.
Quanterix (QTRX) Advances in Alzheimer's Diagnosis With LucentAD
10 July 2023
Quanterix (QTRX) LucentAD biomarker blood test aims to assist healthcare providers in evaluating patients who show cognitive symptoms consistent with the early signs of AD.
Quanterix Corporation (QTRX) Surges 13.6%: Is This an Indication of Further Gains?
10 July 2023
Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt...